1. thepumphandle
  2. Strengthening the FDA: Start with a Conversation

Strengthening the FDA: Start with a Conversation

By sb admin on February 8, 2007.

 by Susan F. Wood, PhD

On Wednesday Feb 21 at 3:00, the project on Scientific Knowledge and Public Policy at GWU School of Public Health and Health Services is hosting what hopefully will be a very exciting afternoon.  Former Commissioners of the FDA will gather to discuss the future of FDA, bringing their experience and priorities together for an unscripted public conversation.  FDA faces many challenges - some new, some old - but we need new ideas to help shape the upcoming legislative proposals that Congress will be taking up this year.  Hearing from several former commissioners, including David Kessler, Jane Henney, Don Kennedy, Frank Young and hopefully Mark McClellan will bring focus to the critical functioning of FDA. 

This "Conversation with FDA Commissioners" is open to the public and the press and will be webcast the next day on Kaisernetwork.org.  It will be held from  3:00-5:00 on Wednesday, Feb. 21 at the Jack Morton Auditorium, 805 21st St. NW, Washington, DC 20052.  If you would like to attend rsvp to Janet at eohjip@gwumc.edu .

The following day, an invitation only workshop of former FDA leaders, scientists, and legal experts will gather to discuss issues of how to improve the use of science at the FDA, the impact of resources, and independance. 

With PDUFA reauthorization just around the corner, new but limited initiatives underway on drug safety, ongoing problems with food safety, and a host of other FDA issues, now is the time to get new ideas on the table.  (Background on this issues is available on SKAPP's website.) Hopefully these efforts will add to the conversation. 

Susan Wood is Research Professor at George Washington University School of Public Health and Health Services, where she is part of the Project on Scientific Knowledge and Public Policy (SKAPP).

Tags
regulation

More like this

Former FDA Commissioners on Credibility, Drug Review, and Other Agency Challenges
By Liz Borkowski Last week, the Project on Scientific Knowledge and Public Policy (SKAPP) held a panel discussion on the FDA featuring four former FDA Commissioners. While all of the panelists made a point of saying that there are a lot of wonderful people working at the FDA, they also…
FDA legislative action, now with commentary from the New England Journal of Medicine
By Susan Wood Next week both the Senate and House are moving forward on legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), along with other key FDA legislation.  The Senate will be âmarking upâ a large omnibus piece of legislation that combines PDUFA with drug safety…
Who Supports FDA User Fees?
When you go to the Department of Motor Vehicles and pay your fee to register your car, are you allowed to negotiate with the DMV as to how the agency will use your fee? Of course not. So why is the drug industry allowed to negotiate with the FDA about how the agency will use the money it collects…
FDA and Drug Safety - what happened to the IOM report?
 By Susan F. Wood, PhD  In an article in the New England Journal of Medicine today, Sheila Weiss Smith points out that the FDA has not been responsive to the Institute of Medicine (IOM) report on Drug Safety.  That study and its recommendations took on the question of how to improve our nation's…